<DOC>
	<DOCNO>NCT01785602</DOCNO>
	<brief_summary>The purpose study determine whether QAW039 safe beneficial effect people moderate severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Efficacy Safety Study QAW039 Treatment Patients With Moderate Severe Atopic Dermatitis .</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key Presence atopic dermatitis confirm Itchy skin condition past 12 month plus three , , follow : History involvement skin crease ( front elbow , behind knee , front ankle , around neck around eye ) Personal history asthma hay fever History generally dry skin past year Onset age 2 year Visible flexural dermatitis Patients EASI score â‰¥15 screen stable AD ( currently experience acute flare AD ) . Patients treat topical corticosteroid topical calcineurin inhibitor least one occasion , could use topical drug ( due contraindication , side effect , etc . ) candidate previously receive systemic treatment . Key History hypersensitivity study drug ( include local anesthesia ) drug similar chemical class ( CRTh2 antagonist ) History serious allergic reaction allergen , anaphylactic shock lifethreatening asthma , prior intubation , respiratory arrest , hospitalization due asthma within last 3 month seizure result asthma History clinically significant ECG abnormality screening/baseline ECG demonstrate clinical significant abnormality could affect patient safety interpretation study result History long QT syndrome whose QTc interval ( Frederica 's ) prolong ( &gt; 450 msec male female ) screen Use topical prescription treatment ( e.g. , topical corticosteroid , calcineurin inhibitor , antibiotic , etc . ) within two week prior initial dose study drug . Patient use emollient encourage Exception : For local atopic dermatitis flare 2week interval , mild topical corticosteroid may take short term ( one week ) Recent previous systemic treatment phototherapy , systemic antihistamine , immunosuppressive agent ( e.g. , cyclosporine , mycophenolate , oral tacrolimus , include therapeutic protein ) Patients maintenance immunotherapy either begin allergen specific immunotherapy regimen clinically relevant change immunotherapy within one month prior grant inform consent Patients highdose statin therapy ( &gt; 40 mg fluvastatin 20 mg simvastatin , atorvastin , pravastatin , rosuvastatin [ 10 mg Asian ] ) Excessive exposure UV light three week prior study start ( screen ) , include tan sun bed and/or plan excessive sunbathe beach holiday associate sun bathing treatment period History hypertrophic scar Body mass index &lt; 17 &gt; 40 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Atopic eczema</keyword>
	<keyword>Skin Diseases</keyword>
</DOC>